Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HitGen Collaborates with Kymera to Identify Protein Degradation Targets

publication date: Jan 15, 2020

HitGen, a Chengdu drug discovery company, will collaborate with Kymera Therapeutics of Cambridge, MA to identify small molecule leads for Kymera targets. Kymera is developing drug candidates that cause protein degradation to treat disease. Its goal is use the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. HitGen will apply its DNA-encoded libraries (DEL) to discover compounds that bind to Kymera targets. Kymera will own the rights to the compounds. HitGen will receive an undisclosed upfront payment from Kymera and be eligible for milestone payments. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital